Journal of Scientometric Research logo
Back

JSCIRES · Lens · Bibliometric Analysis to Explore Trends of the 100 Most Cited Articles in Population Pharmacokinetic and/or Pharmacodynamic Modelling

PDF

Article · Volume 14, Issue 2 · pp. 706-736

Bibliometric Analysis to Explore Trends of the 100 Most Cited Articles in Population Pharmacokinetic and/or Pharmacodynamic Modelling

Nur Mardhiya Darnalis1,2, Hadzliana Zainal2, Eva Germovsek3

  1. 1Department of Pharmacy, Hospital Kulim, Kedah, MALAYSIA.
  2. 2School of Pharmaceutical Sciences, Universiti Sains Malaysia, Pulau Pinang, MALAYSIA.
  3. 3Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH and Co. KG, Ingelheim, GERMANY.

Abstract

Population pharmacokinetic and/or pharmacodynamic [PK(/PD)] modelling has become more popular in drug development and academic research. However, there are no reports exploring the research trends in this area. To explore the (research) trends of most cited articles on PK(/PD) modelling, we bibliometrically analysed the most cited articles (n=100) extracted from the Scopus online database from inception (1964-2021) and again in the recent years (2015-2021) using VOSviewer v1.6.15 and Publish or Perish v8 software. Information such as ATC/drug class, model type, software used, studied population, authors’ institutions, journals, collaborations between countries, and funding sources was extracted and compared. Majority of the studies (65%) described in the 100 most cited articles were population PK modelling studies, with the proportion of the population PKPD modelling studies increasing over time (from 30 to 43%). A large percentage of the impactful articles (43%) were published by top five journals, analysed adult data (84%) and used NONMEM® (80%), which has not changed much over time. Most of the impactful articles studied chemotherapeutic and immunomodulating (33%), anti-infective (29%), and central nervous system (22%) ATC class of drugs, with articles analysing immunosuppressant drug class increasing the most over time (from 10% to 18%). In conclusion, we used a bibliometric approach and investigated research trends in top 100 most cited articles involving PK (/PD) modelling. Apart from the changes mentioned above most other metrics that we compared remained relatively unchanged over time.

Keywords: Keywords; POPPK; Nonlinear mixed effect model; Citation analysis; NONMEM

FULL TEXT

INTRODUCTION

Understanding the dose-concentration-effect relationship is a fundamental concept in clinical pharmacology. Mathematical and statistical models are often used to help describing the above mentioned relationship.[1] More specifically, such models are: population pharmacokinetic (PK) models [to describe the relationship between drug dose and concentration], pharmacodynamic (PD) models [to describe the time course of the biomarkers/safety/efficacy], and pharmacokinetic-pharmacodynamic (PKPD) models [incorporates both PK and PD to describe the relationship between drug dose and/or concentration and effect].[2] PKPD modelling and simulation (M&S) plays an important role in drug development and is promoted by the regulatory agencies, including the United States Food and Drug Administration (FDA) and European Medicines Agency (EMA) to improve efficiency and productivity in pharmaceutical drug development.[3–5]

Several methods for determining drug population pharmacokinetics have been proposed, such as the naïve average data approach, naïve pooled data analysis, a two-stage approach, and a Nonlinear Mixed-Effects (NLME) modelling approach.[6] Human patients differ from one another, therefore their drug disposition and pharmacodynamic effects are heterogenous. To be able to describe the PK (and PD) parameters without bias, an approach that does not over- or underestimate such between patient variability is needed. Comparing the above-mentioned modelling approaches, the mixed-effects modelling approach provides estimates of such variability that are more accurate and less biased.[6] The NLME approach is implemented in many general and specialised statistical tools[7, 8] and it is the most widely used population-based modelling,[9, 10] possibly due to its advantage of being able to handle sparse and unbalanced data (i.e. data where the number of observations and/or sampling times differs between individuals) better compared to other approaches. Furthermore, an NLME model can quantitatively describe the effects of covariates (e.g., sex, age, body weight) on the PK data.[11, 12] Thus, this study only focused on the analyses that used the NLME approach.

Bibliometric analysis is a scientific technique that identifies central concepts, emerging trends, and areas of study interest in certain subjects or research domains by fusing statistical techniques with information visualisation technologies.[13] Citation counts have long been used to assess the quality of research articles and the contributions and scientific performance of scientists, research groups, departments, and universities. These data have been frequently used to make, for example, key policy, performance, career advancement, award selection, and funding decisions.[14] Furthermore, bibliometric analysis allows researchers to identify key study topics and explore the trends in a field, and thus providing ideas and directions for future research.[15]

Hitherto, there has been no bibliometric analysis or other analysis, focusing also on the research trends of most cited articles in the population PK, PD, or PKPD modelling. Hence, we designed a bibliometric study to analyse the top 100 most cited articles since inception (1964-2021) and in the recent years (2015-2021) to explore the trends of most cited papers using data from the Scopus database.

METHODOLOGY

Available data

Information on the 100 most cited articles on population NLME PK (/PD) modelling since inception and in the recent years was obtained from the Scopus online database. The search for articles on population modelling, specifically PK or PD or PKPD modelling studies, was restricted to the article title, abstract, keywords, and studies published by the end of 2021. The Scopus database was accessed in February 2022, to perform searches for overall top 100 most cited articles, and again in August 2022, to search for publications published between 2015-2021. The following query string was used: TITLE-ABS-KEY ("population pharmacokinetic* model*" OR “pharmacokinetic* model*" OR "population pharmacokinetic*" OR "population pharmacodynamic*" OR "pharmacodynamic* model*" "pharmacokinetic* pharmacodynamic* model*" OR "nonlinear mixed effect* model*") AND PUBYEAR < 2022.

Key data from the Scopus database were merged with data from manual search approaches to ensure data accuracy and comprehensiveness. Information collected from the Scopus database included the article’s title, abstract, keywords, publication year, publication types, the number of citations, name of authors, authors’ countries, organisations, journals, and funding. Furthermore, information from journal quartiles and Anatomical Therapeutic Chemical (ATC) Classification were retrieved manually to supplement the Scopus information. In this regard, we referenced the SCImago Journal Rank (SJR) 2021 edition[16] to determine journal quartiles, while the therapeutic class was identified based on the Anatomical Therapeutic Chemical (ATC) Classification system at the first (main anatomical group) and second level (drug classes).

Each publication was reviewed to ensure that the study refers to the population PK or PD or PKPD modelling rather than other fields like software development. Full texts of the articles were retrieved where necessary.

The full inclusion criteria are outlined below:

  1. Original articles related to the development, evaluation or validation, and application of population pharmacokinetic and/or pharmacodynamic models.
  2. Population data were analysed using a Nonlinear Mixed Effect (NLME) modelling approach.

The exclusion criteria included reviews, methodology articles, and preclinical in vitro and in vivo studies. Figure 1 describes the selection process for the years 1964-2021 and Supplementary Figure 1 describes the selection process for the years 2015-2021 based on the PRISMA 2009 flow diagram.[17] No ethics approval was required since this study was a bibliometric analysis with no human/animal subjects involved.

Bibliometric and Visualisation Analysis

Harzing’s Publish or Perish software v8 was used to import data from the Scopus database to determine each article’s citations per year. To map and visualise the co-authorship relationship between countries of the authors we produced network maps via VOSviewer 1.6.15 software (www.vosviewer.com).

Figure 1: PRISMA flowchart illustrating the selection process of the 100 most cited articles about PK(/PD) modelling between 1964 and 2021.: * Articles with <150 citations were excluded to ensure only top 100 most cited articles remained PRISMA Preferred Reporting Items for Systematic Reviews and Meta-Analyses.

RESULTS

Characteristics of the 100 most cited population PK, PD, or PKPD modelling

The number of citations ranged from 137 to 914 and 37 to 156 for the 100 most cited articles since inception and in the recent years, respectively. Most of the 100 most cited articles since inception were published in 2008 (n=10) involving anti-infectives, central nervous system agents, and chemotherapeutics and immunomodulating agents, while most articles in the recent years were published in 2015 (n=45) with a similar scope of studies. The Supplementary Table 1 lists the 100 most cited articles on population PK, PD, or PKPD modelling since inception to 2021 based on the number of citations in descending order. Meanwhile, the most cited articles published 2015-2021 are listed in Supplementary Table 2.

The article “Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil I. Model development”[18] has the highest number of total citations since inception until 2021 (n=914). Whereas “Population pharmacokinetics of colistin methane sulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients”[19] has the highest citation rate per year with an average of 48.82 citations per year (Supplementary Table 1). Eighty-eight percent of the 100 most cited articles since inception were published in Quartile 1 journals, which increased to 91% in recent years.

Anatomical therapeutic classification groups/drug classes

The most studied ATC class of drugs in the top 100 most cited articles were chemotherapeutics and immunomodulating agents (33%), with anti-infectives (29%) and central nervous system ATC class (22%) represented similarly in the second and third place (Figure 2). In the recent 100 most cited articles the trends remained similar, with the number of studies analysing the chemotherapeutic and immunomodulating agents, and anti-infective ATC drug class increasing (42% and 39%, respectively) whereas the number of central nervous system ATC class reduced (9%). Detailed information on each ATC group and the respective drug classes is summarised in Figure 2.

Antineoplastic agents (23%), antibacterials (13%) and anaesthetics (11%) were the top 3 drug classes in the 100 most cited articles since inception. However, the percentage of influential papers publishing antibacterial modelling results increased recently to 20%, with antineoplastic agents staying relatively the same (24%) and increasing to third place is immunosuppressant drugs (18%) (Figure 2). Detailed information for these drug classes is listed in Supplementary Tables 3-5. The most significant changes within the impactful articles reporting results on antineoplastic, antibacterial, and immunosuppressant drug classes are summarised below, other than that there have not been any major research trend changes. The proportion of studies in paediatric population increased in all the three drug classes. Additionally, most antibacterial studies shifted from polymyxins (42%) to glycopeptide antibiotics (37%) in the recent years (Supplementary Table 4) and for immunosuppressant drugs the trend changed from tumour necrosis factor-alpha inhibitors (44%) to selective immunosuppressants (53%) (Supplementary Table 5).

Type of study, investigated population and software used

Most of the studies described in the top 100 most cited articles were population PK studies (65%) followed by population PKPD modelling studies (30%) (Table 1). Recently, the number of population PK modelling studies decreased (55%) and the number of populations PKPD modelling studies increased (43%). PD studies represented only ≤5% of the studies throughout the years (Table 1).

The classification of PKPD modelling study was determined if the article used at least one population PK and/or PD model, e.g. a study of population PK, combined with a PKPD metric for the PD part was counted as a PKPD modelling study.

Majority of the impactful articles reported analyses of the adult population compared to the paediatric populations (Table 2), with only a small increase in the percentage (1%) of studies performed in the paediatric population in recent years. In the 100 most cited articles since inception most paediatric studies included children over 2 years (7 out of 12 paediatric studies), however, recently, most studies (6 out of 13 paediatric studies) included a wide distribution of paediatric ages (i.e. from newborn until adolescent) (Table 2).

Eighty percent of the top 100 most cited articles in all publications used NONMEM® software to analyse the PK(/PD) data. Interestingly, this number recently increased (83%) confirming that NONMEM® is still the main software for population analyses (Table 3). Within the most cited research, only a few researchers used different types of software besides NONMEM®, such as, S-ADAPT, NLME, Phoenix NLME, Monolix, SAS software, NPEM2 and NLMIXED (Table 3).

Number of authors, institutions and journals, collaborations, and funding sources

The number of authors ranged from 1 to 20 (median 8 authors) and 3 to 32 (median 9 authors) for the 100 most cited publications and the top 100 most cited publications in recent years, respectively.

Table 4 shows the top six institutions that were affiliated with authors who published the 100 most cited population PK, PD or PKPD modelling analyses. Out of these, three institutions were from the European Union and two were from the US, however, recently, 5 out of the top 6 institutions (except University of Queensland) were from Europe. The institution that contributed the most to the 100 most cited articles since inception was Uppsala University (8%), but recently, University of Liverpool and Leiden University Medical Center both contributed as much as Uppsala University (6%) (Table 4).

The 100 most cited articles were published in 39 academic journals and 38 academic journals for overall years and recent years, respectively. The majority of these impactful articles since inception were published in Anesthesiology, however, recently, the impactful research has been mostly published in Antimicrobial Agents and Chemotherapy (Table 5). Top 5 journals that published more than 40% of the 100 most cited articles since inception and in recent years, remained mostly unchanged over time. Nevertheless, in the recent years, Clinical Pharmacokinetics entered the top 5, replacing Anesthesiology. Detailed information on the top journals and their SCImago Journal Ranking (SJR) value is given in Table 5.

Co-authorship network analyses showed that the circle representing United States was the largest indicating the most publications (Figures 3 and 4). United States also had the highest total link strength of 54 (Table 6) which even increased recently (to 65), making USA the most prominent collaborating country. The Netherlands and United Kingdom remained in the top three most prominent countries. The collaboration between countries has, however, changed slightly over time. In the overall 100 most cited articles researchers collaborated most with and between developed countries, such as, United States and Germany or Sweden (Figure 3), but recently, an increasing number of researchers from developing countries (such as South Africa and China) collaborated with those from a developed country (Figure 4).

Table 7 summarises the funding status for the 100 most cited articles. Unfortunately, not all publications reported the founding source: in the top 100 most cited publications 20 did not report it, however, this improved with time (to n=7). More than 70% of the studies received funding locally since inception, but in the top 100 most cited articles published recently, there was a slight increase (2%) of international funding (Table 7). As an example, one study from a developing country (South Africa) received funds from the World Health Organization, and the United States Agency for International Development.[21]

Table 1: Types of population modelling studies in the top 100 cited articles on PK(/PD) modelling.
Type of population modelling studiesPercentage of articles
1964-20212015-2021
Population Pharmacokinetic (PK)65 %55%
Population Pharmacodynamic (PD)5 %2 %
Population Pharmacokinetic-Pharmacodynamic (PKPD)a30 %43 %
Table 2: Study population used in the top 100 cited articles about PK (/PD) modelling.
Study populationPercentage of articles
1964 -20212015-2021
Adults84%80%
Paediatric patientsa12%13%
Newborns (<1 month)1%-
Infants and toddlers (1 month to <2years)2%3%
Children (2-11 years)7%1%
Adolescents (12-18 years)1%3%
More than in 1 subcategory1%6%
Paediatric and adult patients4 %7 %
Table 3: Types of population modelling software used in the top 100 cited articles about PK (/PD) modelling.
Type of population modelling software usedPercentage of articles
1964 -20212015-2021
NONMEM®80 %83 %
Other software18 %15 %
Pmetrics5%
Phoenix NLME1%4%
Monolix-4%
NPAG3%-
S-ADAPT3%2%
ADAPT21%-
NLME3%-
P-Pharm1%-
WinNonMix1%-
NPEM2%-
NLMIXED2%-
SAS1%
Software not mentioned2%2%
Table 4: Top six institutions whose researchers published the top 100 most cited articles about PK (/PD) modelling.
1964-20212015-2021
InstitutionsPercentage of articlesInstitutionsPercentage of articles
Uppsala University, Sweden8%Uppsala University, Sweden6%
Standford University, United States5%University of Liverpool, United Kingdom6%
University at Buffalo, United States4%Leiden University Medical Center, Netherlands6%
Leiden University Medical Center, Netherlands4%Erasmus Medical Centre-Sophia Children's Hospital, Netherlands5%
University of Queensland, Australia4%University Medical Center Groningen, Netherlands5%
Erasmus Medical Centre, Netherlands3%University of Queensland, Australia5%
Table 5: Top five journals that published the top 100 most cited articles about PK (/PD) modelling.
1964-20212015-2021
JournalPercentage of articlesSJR 2021JournalPercentage of articlesSJR 2021
Anesthesiology16%1.65Antimicrobial Agents and Chemotherapy14%1.55
Antimicrobial Agents and Chemotherapy13%1.55Clinical Pharmacokinetics11%1.27
Clinical Pharmacology and Therapeutics5%1.69British Journal of Clinical Pharmacology9%1.06
British Journal of Clinical Pharmacology5%1.06Clinical Pharmacology and Therapeutics6%1.69
Journal of Clinical Pharmacology4%0.69Journal of Clinical Pharmacology4%0.69
Table 6: Total link strength of co-authorship between top 10 countries in the 100 most cited articles about PK (/PD) modelling.
1964-20212015-2021
RankCountryTotal Link strengthRankCountryTotal Link strength
1United States541United States65
2Netherlands352United Kingdom46
3United Kingdom283Netherlands43
4Sweden264Switzerland28
5Germany215Germany25
6Canada196Sweden24
7Switzerland137Belgium21
8Australia108France19
9Italy109Australia17
10Brazil710Canada10
Table 7: Funding information on the top 100 most cited PK (/PD) modelling studies.
Funding informationPercentage of articles
1964-20212015-2021
Received grant/funding74%82%
Local funding23%37%
Public sector50%37%
Private sector1%8%
Combination of public and private sector4%6%
International funding2%5%
Received no funding20%7%
Funding information not stated20%7%
Supplementary Table 1: 100 most cited articles reporting population PK, PD or PKPD modelling analyses for overall publications since 1964 until 2021.
Rank.First authorYearTitleJournalSCImago Journal Quartile 2021Number of citationsaCitations per year
1.Minto CF1997Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil I. Model developmentAnesthesiologyQ191436.56
2.Preston SL1998Pharmacodynamics of levofloxacin: A new paradigm for early clinical trialsJournal of the American Medical AssociationQ158524.38
3.Padayatty SJ2004Vitamin C Pharmacokinetics: Implications for Oral and Intravenous UseAnnals of Internal MedicineQ157932.17
4.Garonzik SM2011Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patientsAntimicrobial Agents and ChemotherapyQ153748.82
5.Minto CF1997Pharmacokinetics and pharmacodynamics of remifentanil II. Model applicationAnesthesiologyQ153021.20
6.Palmer S2008Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapyProceedings of the National Academy of Sciences of the United States of AmericaQ150936.36
7.Egan TD1993The pharmacokinetics of the new short-acting opioid remifentanil (GI87084B) in healthy adult male volunteersAnesthesiologyQ148416.69
8.Plachouras D2009Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteriaAntimicrobial Agents and ChemotherapyQ139330.23
9.Bruno R1998Population pharmacokinetics/pharmacodynamics of docetaxel in phase ii studies in patients with cancerJournal of Clinical OncologyQ138015.83
10.Scott JC1985EEG quantitation of narcotic effect: The comparative pharmacodynamics of fentanyl and alfentanilAnesthesiologyQ138010.27
11.Friberg LE2002Model of chemotherapy-induced myelosuppression with parameter consistency across drugsJournal of Clinical OncologyQ136518.25
12.Avramis VI2002A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: A Children’s Cancer Group studyBloodQ135517.75
13.Egan TD1996Remifentanil versus alfentanil: Comparative pharmacokinetics and pharmacodynamics in healthy adult male volunteersAnesthesiologyQ134513.27
14.Schüttler J2000Population pharmacokinetics of propofol: A multicenter studyAnesthesiologyQ133215.09
15.Ostermann S2004Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patientsClinical Cancer ResearchQ132618.11
16.Sarton E2000Sex differences in morphine analgesia: An experimental study in healthy volunteersAnesthesiologyQ131914.50
17.Rosenfeld MR2014A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiformeAutophagyQ130938.63
18.Bruhn J2000Approximate entropy as an electroencephalographic measure of anesthetic drug effect during desflurane anesthesiaAnesthesiologyQ130413.82
19.Ezzet F2000Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malariaAntimicrobial Agents and ChemotherapyQ127312.41
20.Mueck W2011Rivaroxaban: Population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke preventionClinical PharmacokineticsQ127124.64
21.Walsh TJ2004Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administrationAntimicrobial Agents and ChemotherapyQ126714.83
22.Lu JF2008Clinical pharmacokinetics of bevacizumab in patients with solid tumorsCancer Chemotherapy and PharmacologyQ126418.86
23.Kataria BK1994The pharmacokinetics of propofol in children using three different data analysis approachesAnesthesiologyQ12599.25
24.Sandri AM2013Population pharmacokinetics of intravenous polymyxin B in critically Ill patients: Implications for selection of dosage regimensClinical Infectious DiseasesQ125628.44
25.Olofsen E2008Permutation entropy of the electroencephalogram: A measure of anaesthetic drug effectBritish Journal of AnaesthesiaQ125418.14
26.Roberts JA2009Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: Intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distributionJournal of Antimicrobial ChemotherapyQ125019.23
27.Chatelut E1995Prediction of carboplatin clearance from standard morphological and biological patient characteristicsJournal of the National Cancer InstituteQ12489.19
28.Liesenfeld KH2011Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trialJournal of Thrombosis and HaemostasisQ124622.36
29.Mueck W2008Population pharmacokinetics and pharmacodynamics of once-and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacementThrombosis and HaemostasisQ124617.57
30.Bruno R1996A population pharmacokinetic model for docetaxel (Taxotere®): Model building and validationJournal of Pharmacokinetics and Biopharmaceuticsn/a2379.12
31.Fasanmade AA2009Population pharmacokinetic analysis of infliximab in patients with ulcerative colitisEuropean Journal of Clinical PharmacologyQ223518.08
32.Thuresson K2006Apparent half-lives of hepta- to decabrominated diphenyl ethers in human serum as determined in occupationally exposed workersEnvironmental Health PerspectivesQ123514.69
33.Csajka C2003Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infectionClinical Pharmacology and TherapeuticsQ123112.16
34.Haas DW2005Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfinavir: An adult AIDS clinical trials group studyJournal of Infectious DiseasesQ122713.35
35.Rangwala R2014Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanomaAutophagyQ122327.88
36.Mueck W2008Population pharmacokinetics and pharmacodynamics of rivaroxaban - An oral, direct factor Xa inhibitor - In patients undergoing major orthopaedic surgeryClinical PharmacokineticsQ121515.36
37.Kirchheiner2003Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6Pharmacogeneticsn/a21511.32
38.Kumar SK2014Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: An open-label phase 1/2 studyThe Lancet OncologyQ121326.63
39.Yacyshyn BR2002Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn’s diseaseGutQ120910.45
40.Drusano GL2004Relationship between fluoroquinolone area under the curve:minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumoniaJournal of Infectious DiseasesQ120711.50
41.Li C2007Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infectionsAntimicrobial Agents and ChemotherapyQ120213.47
42.Greenberg PL2004Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: A phase III trial (E2995)Journal of Clinical OncologyQ119811.00
43.Houk BE2009A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patientsClinical Cancer ResearchQ119715.15
44.Fasanmade AA2011Pharmacokinetic Properties of Infliximab in Children and Adults with Crohn’s Disease: A Retrospective Analysis of Data from 2 Phase III Clinical TrialsClinical TherapeuticsQ219617.82
45.Bruno R2005Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancerCancer Chemotherapy and PharmacologyQ119411.41
46.Carducci MA2001A phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion scheduleClinical Cancer ResearchQ11929.14
47.Kirchheiner J2002Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteersClinical Pharmacology and TherapeuticsQ11869.30
48.Stewart MW2012Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye)RetinaQ118518.50
49.Rudin CM2008Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicityJournal of Clinical OncologyQ118513.21
50.Lu JF2006Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancerClinical Pharmacology and TherapeuticsQ118311.44
51.Venn RM2002Pharmacokinetics of dexmedetomidine infusions for sedation of postoperative patients requiring intensive careBritish Journal of AnaesthesiaQ11829.10
52.Anderson BJ2002Acetaminophen developmental pharmacokinetics in premature neonates and infants: A pooled population analysisAnesthesiologyQ11829.10
53.Müller C2012The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCLBloodQ118118.10
54.Peloquin CA1997Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamideAntimicrobial Agents and ChemotherapyQ11817.24
55.Kirchheiner J2002Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteersPharmacogeneticsn/a1798.95
56.Neely M2010Voriconazole pharmacokinetics and pharmacodynamics in childrenClinical Infectious DiseasesQ117714.75
57.Mertens-Talcott SU2008Pharmacokinetics of anthocyanins and antioxidant effects after the consumption of anthocyanin-rich açai juice and pulp (Euterpe oleracea Mart.) in human healthy volunteersJournal of Agricultural and Food ChemistryQ117612.57
58.Sparr HJ2007Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: Efficacy, safety, and pharmacokineticsAnesthesiologyQ117411.6
59.Ezzet F1998Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patientsBritish Journal of Clinical PharmacologyQ11747.25
60.Judson I2005Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: A retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma GroupCancer Chemotherapy and PharmacologyQ117310.18
61.Van Hest RM2006Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: A population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipientsJournal of the American Society of NephrologyQ117210.75
62.Dotan I2014Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: A population pharmacokinetic studyInflammatory Bowel DiseasesQ117121.38
63.Petroz GC2006A phase I, two-center study of the pharmacokinetics and pharmacodynamics of dexmedetomidine in childrenAnesthesiologyQ117010.63
64.Karlsson MO2009Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studiesAntimicrobial Agents and ChemotherapyQ116913.00
65.Hsu A1997Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjectsAntimicrobial Agents and ChemotherapyQ11686.72
66.Maitre PO1987Population pharmacokinetics of alfentanil: The average dose-plasma concentration relationship and interindividual variability in patientsAnesthesiologyQ11684.80
67.Pascual A2012Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: Population pharmacokinetics-based analysis of adult patients with invasive fungal infectionsClinical Infectious DiseasesQ116616.60
68.Zhou H2007Pharmacokinetics and safety of golimumab, a fully human anti-TNF-α monoclonal antibody, in subjects with rheumatoid arthritisJournal of Clinical PharmacologyQ216511.00
69.Ng CM2005Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trialJournal of Clinical PharmacologyQ21649.65
70.Moon YJ2008Quercetin pharmacokinetics in humansBiopharmaceutics and Drug DispositionQ216411.71
71.Mohamed AF2012Application of a loading dose of colistin methanesulfonate in critically ill patients: Population pharmacokinetics, protein binding, and prediction of bacterial killAntimicrobial Agents and ChemotherapyQ116316.3
72.Yates CR2003The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patientsJournal of Clinical PharmacologyQ21638.58
73.Dowd NP2002Pharmacokinetics of tranexamic acid during cardiopulmonary bypassAnesthesiologyQ11618.05
74.Mamiya K1998The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: Studies in stereoselective hydroxylation and population pharmacokineticsEpilepsiaQ11616.71
75.Kinzig-Schippers M2005Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses?Antimicrobial Agents and ChemotherapyQ11609.41
76.Henningsson A2005Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxelClinical Cancer ResearchQ11599.35
77.Hesselink DA2004Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genesClinical Pharmacology and TherapeuticsQ11598.83
78.Hsu A1998Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavirClinical Pharmacology and TherapeuticsQ11586.58
79.Admiraal R2015Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysisThe Lancet HaematologyQ115622.29
80.Roberts JA2011Vancomycin dosing in critically ill patients: Robust methods for improved continuous-infusion regimensAntimicrobial Agents and ChemotherapyQ115414.00
81.Nyakutira C2008High prevalence of the CYP2B6 516G-->T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in ZimbabweEuropean Journal of Clinical PharmacologyQ215411.00
82.Smith PF2007Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of Single-Dose 3-O-(3′,3′-Dimethylsuccinyl)Betulinic Acid (bevirimat) against human immunodeficiency virus InfectionAntimicrobial Agents and ChemotherapyQ115410.27
83.Birmingham PK1997Twenty-four-hour pharmacokinetics of rectal acetaminophen in children: An old drug with new recommendationsAnesthesiologyQ11546.16
84.Björkman S2012Population pharmacokinetics of recombinant factor VIII: The relationships of pharmacokinetics to age and body weightBloodQ115315.3
85.Peloquin CA2008Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosisAntimicrobial Agents and ChemotherapyQ115210.86
86.Wright JG2001Estimation of glomerular filtration rate in cancer patientsBritish Journal of CancerQ11517.19
87.Dowell JA2004Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungalJournal of Clinical PharmacologyQ21508.33
88.Wu L2002A joint model for nonlinear mixed-effects models with censoring and covariates measured with error, with application to AIDS studiesJournal of the American Statistical AssociationQ11507.50
89.Anderson BJ1999Perioperative pharmacodynamics of acetaminophen analgesia in childrenAnesthesiologyQ11496.48
90.Rosario M2015Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn’s diseaseAlimentary Pharmacology and TherapeuticsQ114620.86
91.Widmer N2006Population pharmacokinetics of imatinib and the role of α1‐acid glycoproteinBritish Journal of Clinical PharmacologyQ11459.06
92.Bellnier DA2003Population pharmacokinetics of the photodynamic therapy agent 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a in cancer patientsCancer ResearchQ11457.63
93.Hayashi N2007A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumabBritish Journal of Clinical PharmacologyQ11439.53
94.Ballantyne CM2015Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemiaAmerican Journal of CardiologyQ114220.29
95.Kappelhoff BS2005Are adverse events of nevirapine and efavirenz related to plasma concentrations?Antiviral TherapyQ21428.35
96.Bajaj G2017Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients with Solid TumorsCPT: Pharmacometrics and Systems PharmacologyQ114028.00
97.Anderson BJ2000A model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and childrenBritish Journal of Clinical PharmacologyQ11406.36
98.Nation RL2017Dosing guidance for intravenous colistin in critically ill patientsClinical Infectious DiseasesQ113927.80
99.Ariano RE2005Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremiaAnnals of PharmacotherapyQ11378.06
100.Mandema JW1996Characterization and validation of a pharmacokinetic model for controlled-release oxycodoneBritish Journal of Clinical PharmacologyQ11375.27
Supplementary Table 2: 100 most cited articles reporting population PK, PD or PKPD modelling analyses in the last 7 years (2015 -2021).
RankFirst authorYearTitleJournalSCImago Journal Quartile 2021Number of citationsaCitations per year
1.Admiraal R2015Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysisThe Lancet HaematologyQ115622.29
2.Rosario M2015Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn’s diseaseAlimentary Pharmacology and TherapeuticsQ114620.86
3.Ballantyne CM2015Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemiaAmerican Journal of CardiologyQ114220.29
4.Bajaj G2017Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients with Solid TumorsCPT: Pharmacometrics and Systems PharmacologyQ114028.00
5.Nation RL2017Dosing guidance for intravenous colistin in critically ill patientsClinical Infectious DiseasesQ113927.80
6.Blank A2016First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex BJournal of HepatologyQ112220.33
7.Freshwater T2017Evaluation of dosing strategy for pembrolizumab for oncology indicationsJournal for ImmunoTherapy of CancerQ112124.20
8.Bartelink IH2016Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysisThe Lancet HaematologyQ111218.67
9.Xiao AJ2016Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumoniaJournal of Clinical PharmacologyQ211122.20
10.Zhao X2017Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumorsAnnals of OncologyQ111118.50
11.Admiraal R2017Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a multicentre, retrospective, pharmacodynamic cohort analysisThe Lancet HaematologyQ110921.80
12.Dunne MW2015Extended-duration dosing and distribution of dalbavancin into bone and articular tissueAntimicrobial Agents and ChemotherapyQ19413.43
13.Zhu M2016Blinatumomab, a Bispecific T-cell Engager (BiTE®) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its ImplicationsClinical PharmacokineticsQ19215.33
14.Admiraal R2016Excellent T-cell reconstitution and survival depend on low ATG exposure after pediatric cord blood transplantationBloodQ19015.00
15.Namour F2015Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose SelectionClinical PharmacokineticsQ18812.57
16.Brandse JF2017A Real-life Population Pharmacokinetic Study Reveals Factors Associated with Clearance and Immunogenicity of Infliximab in Inflammatory Bowel DiseaseInflammatory Bowel DiseasesQ17915.80
17.De Grooth HJ2018Vitamin C Pharmacokinetics in Critically Ill Patients: A Randomized Trial of Four IV RegimensChestQ17819.50
18.Eleveld DJ2018Pharmacokinetic–pharmacodynamic model for propofol for broad application in anaesthesia and sedationBritish Journal of AnaesthesiaQ17418.50
19.Karaiskos I2015Colistin population pharmacokinetics after application of a loading dose of 9 MU colistin methanesulfonate in critically ill patientsAntimicrobial Agents and ChemotherapyQ17410.57
20.Varenhorst C2015Effect of genetic variations on ticagrelor plasma levels and clinical outcomesEuropean Heart JournalQ17410.57
21.Baverel PG2018Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease StatusClinical Pharmacology and TherapeuticsQ17117.75
22.Stroh M2017Clinical Pharmacokinetics and Pharmacodynamics of Atezolizumab in Metastatic Urothelial CarcinomaClinical Pharmacology and TherapeuticsQ17114.20
23.Odore E2016Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic MalignanciesClinical PharmacokineticsQ16310.50
24.Chen N2015Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetrationCancer Chemotherapy and PharmacologyQ1618.71
25.Coles LD2018Repeated-Dose Oral N-Acetylcysteine in Parkinson’s Disease: Pharmacokinetics and Effect on Brain Glutathione and Oxidative StressJournal of Clinical PharmacologyQ26015.00
26.McCarthy JS2016A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection studyMalaria JournalQ16010.00
27.Jones AK2016Clinical Predictors of Venetoclax Pharmacokinetics in Chronic Lymphocytic Leukemia and Non-Hodgkin’s Lymphoma Patients: a Pooled Population Pharmacokinetic AnalysisAAPS JournalQ16010.00
28.Størset E2015Improved tacrolimus target concentration achievement using computerized dosing in renal transplant recipients-a prospective, Randomized StudyTransplantationQ1608.57
29.Sharma S2015Pharmacokinetics and exposure-efficacy relationship of adalimumab in pediatric patients with moderate to severe Crohn’s disease: Results from a randomized, multicenter, phase-3 studyInflammatory Bowel DiseasesQ1598.43
30.Katsube T2017Pharmacokinetic/pharmacodynamic modeling and simulation of cefiderocol, a parenteral siderophore cephalosporin, for dose adjustment based on renal functionAntimicrobial Agents and ChemotherapyQ15811.60
31.Desai A2016Population pharmacokinetics of isavuconazole from phase 1 and phase 3 (SECURE) trials in adults and target attainment in patients with invasive infections due to Aspergillus and other filamentous fungiAntimicrobial Agents and ChemotherapyQ1589.67
32.Soy D2015Population pharmacokinetics of benznidazole in adult patients with Chagas diseaseAntimicrobial Agents and ChemotherapyQ1588.29
33.Le J2015Pharmacodynamic characteristics of nephrotoxicity associated with vancomycin use in childrenJournal of the Pediatric Infectious Diseases SocietyQ1588.29
34.Svensson EM2018The potential for treatment shortening with higher rifampicin doses: Relating drug exposure to treatment response in patients with pulmonary tuberculosisClinical Infectious DiseasesQ15513.75
35.Vet NJ2016Inflammation and organ failure severely affect midazolam clearance in critically ill childrenAmerican Journal of Respiratory and Critical Care MedicineQ1559.17
36.Adane ED2015Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infectionsPharmacotherapyQ1557.86
37.Admiraal R2015Population Pharmacokinetic Modeling of Thymoglobulin® in Children Receiving Allogeneic-Hematopoietic Cell Transplantation: Towards Improved Survival Through Individualized DosingClinical PharmacokineticsQ1557.86
38.Wise-Draper TM2017A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid MalignanciesTargeted OncologyQ15410.80
39.Dhoro M2015CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: Population pharmacokinetic modeling in an HIV/AIDS and TB cohort in ZimbabweBMC Pharmacology and ToxicologyQ3547.71
40.Haas NB2019Autophagy inhibition to augment mTOR inhibition: A phase I/II trial of everolimus and hydroxychloroquine in patients with previously treated renal cell carcinomaClinical Cancer ResearchQ15317.67
41.Tamai T2017Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure–Response AnalysesJournal of Clinical PharmacologyQ25310.60
42.Grau S2015Plasma and peritoneal fluid population pharmacokinetics of micafungin in post-surgical patients with severe peritonitisJournal of Antimicrobial ChemotherapyQ1537.57
43.Leroux S2015Pharmacokinetic Studies in Neonates: The Utility of an Opportunistic Sampling DesignClinical PharmacokineticsQ1537.43
44.Long-Boyle JR2015Population pharmacokinetics of busulfan in pediatric and young adult patients undergoing hematopoietic cell transplant: A model-based dosing algorithm for personalized therapy and implementation into routine clinical useTherapeutic Drug MonitoringQ2527.43
45.Satia I2017Capsaicin-evoked cough responses in asthmatic patients: Evidence for airway neuronal dysfunctionJournal of Allergy and Clinical ImmunologyQ15110.20
46.Milosheska D2016Pharmacokinetics of lamotrigine and its metabolite N-2-glucuronide: Influence of polymorphism of UDP-glucuronosyltransferases and drug transportersBritish Journal of Clinical PharmacologyQ1508.33
47.De Cock PAJG2015Augmented renal clearance implies a need for increased amoxicillin-clavulanic acid dosing in critically ill childrenAntimicrobial Agents and ChemotherapyQ1507.14
48.Gupta N2015Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: A population pharmacokinetic analysisBritish Journal of Clinical PharmacologyQ1507.14
49.Andreu F2017A New CYP3A5*3 and CYP3A4*22 Cluster Influencing Tacrolimus Target Concentrations: A Population ApproachClinical PharmacokineticsQ1499.80
50.Chandorkar G2015Population pharmacokinetics of ceftolozane/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infectionsJournal of Clinical PharmacologyQ2497.00
51.Denti P2015Pharmacokinetics of isoniazid, pyrazinamide, and ethambutol in newly diagnosed pulmonary TB patients in TanzaniaPLoS ONEQ1497.00
52.Kim H2018Pharmacokinetics, Pharmacodynamics, and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI PatientsClinical Pharmacology and TherapeuticsQ14812.00
53.Svensson RJ2018A Population Pharmacokinetic Model Incorporating Saturable Pharmacokinetics and Autoinduction for High Rifampicin DosesClinical Pharmacology and TherapeuticsQ14812.00
54.Marostica E2015Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignanciesCancer Chemotherapy and PharmacologyQ1486.86
55.Hannivoort LN2015Development of an optimized pharmacokinetic model of dexmedetomidine using target-controlled infusion in healthy volunteersAnesthesiologyQ1486.86
56.Vu T2017Pharmacokinetic-Pharmacodynamic Relationship of Erenumab (AMG 334) and Capsaicin-Induced Dermal Blood Flow in Healthy and Migraine SubjectsPharmaceutical ResearchQ2479.40
57.Brown K2017Population pharmacokinetics and exposure-response of osimertinib in patients with non-small cell lung cancerBritish Journal of Clinical PharmacologyQ1479.40
58.Dolder PC2017Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy SubjectsClinical PharmacokineticsQ1479.40
59.McCarthy JS2016Efficacy of OZ439 (artefenomel) against early Plasmodium falciparum blood-stage malaria infection in healthy volunteersJournal of Antimicrobial ChemotherapyQ1477.83
60.Bustinduy AL2016Population pharmacokinetics and pharmacodynamics of praziquantel in Ugandan children with intestinal schistosomiasis: Higher dosages are required for maximal efficacymBioQ1477.83
61.Zhao CY2016External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipientsBritish Journal of Clinical PharmacologyQ1477.83
62.Ternant D2015Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritisBritish Journal of Clinical PharmacologyQ1476.71
63.Jaruratanasirikul S2015Population pharmacokinetics and Monte Carlo dosing simulations of meropenem during the early phase of severe sepsis and septic shock in critically ill patients in intensive care unitsClinical Pharmacology and TherapeuticsQ1466.57
64.Fanta S2015Population pharmacokinetics of S-ketamine and norketamine in healthy volunteers after intravenous and oral dosingEuropean Journal of Clinical PharmacologyQ2466.57
65.Neely M2015Achieving target voriconazole concentrations more accurately in children and adolescentsAntimicrobial Agents and ChemotherapyQ1466.57
66.Ulldemolins M2015Meropenem population pharmacokinetics in critically Ill patients with septic shock and continuous renal replacement therapy: Influence of residual diuresis on dose requirementsAntimicrobial Agents and ChemotherapyQ1466.57
67.Klünder B2018Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical TrialsClinical PharmacokineticsQ14511.25
68.Kovalenko P2016Exploratory population PK analysis of Dupilumab, a fully human monoclonal antibody against IL-4Rα, in atopic dermatitis patients and normal volunteersCPT: Pharmacometrics and Systems PharmacologyQ1457.50
69.Frippiat F2015Modelled target attainment after meropenem infusion in patients with severe nosocomial pneumonia: The PROMESSE studyJournal of Antimicrobial ChemotherapyQ1456.43
70.Parker SL2015Population pharmacokinetics of fosfomycin in critically ill patientsAntimicrobial Agents and ChemotherapyQ1456.43
71.Janssen EJH2016Towards rational dosing algorithms for vancomycin in neonates and infants based on population pharmacokinetic modelingAntimicrobial Agents and ChemotherapyQ1447.33
72.Sloan DJ2015Pharmacodynamic modeling of bacillary elimination rates and detection of bacterial lipid bodies in sputum to predict and understand outcomes in treatment of pulmonary tuberculosisClinical Infectious DiseasesQ1446.29
73.Chatterjee M2017Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab-Treated Advanced MelanomaCPT: Pharmacometrics and Systems PharmacologyQ1438.60
74.Savic RM2017Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure–response relations from two phase II clinical trialsClinical Pharmacology and TherapeuticsQ1438.60
75.Gatault P2015Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedulemAbsQ1436.14
76.Yoneyama K2018A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia AClinical PharmacokineticsQ14210.50
77.Eleveld DJ2017An allometric model of remifentanil pharmacokinetics and pharmacodynamicsAnesthesiologyQ1428.40
78.Buurman DJ2015Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: Potential implications for dosing in clinical practiceAlimentary Pharmacology and TherapeuticsQ1426.00
79.Ding J2015A Population Pharmacokinetic Model of Valproic Acid in Pediatric Patients with Epilepsy: A Non-Linear Pharmacokinetic Model Based on Protein-Binding SaturationClinical PharmacokineticsQ1426.00
80.Abuhelwa AY2015Population pharmacokinetic modeling of itraconazole and hydroxyitraconazole for oral SUBA-itraconazole and sporanox capsule formulations in healthy subjects in fed and fasted statesAntimicrobial Agents and ChemotherapyQ1426.00
81.Avedissian SN2017Augmented Renal Clearance Using Population-Based Pharmacokinetic Modeling in Critically Ill Pediatric PatientsPediatric Critical Care MedicineQ1408.00
82.Chirehwa MT2016Model-based evaluation of higher doses of rifampin using a semimechanistic model incorporating autoinduction and saturation of hepatic extractionAntimicrobial Agents and ChemotherapyQ1406.67
83.Gupta A2016Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancerBritish Journal of Clinical PharmacologyQ1406.67
84.Brill MJ2015The Pharmacokinetics of the CYP3A Substrate Midazolam in Morbidly Obese Patients before and One Year after Bariatric SurgeryPharmaceutical ResearchQ2405.71
85.Kovanda LL2016Isavuconazole population pharmacokinetic analysis using nonparametric estimation in patients with invasive fungal disease (results from the VITAL study)Antimicrobial Agents and ChemotherapyQ1396.50
86.Rubino CM2015Population pharmacokinetic analysis for a single 1,200-milligram dose of oritavancin using data from two pivotal phase 3 clinical trialsAntimicrobial Agents and ChemotherapyQ1395.57
87.Panoilia E2015A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patientsCancer Chemotherapy and PharmacologyQ1395.57
88.Boer H2015Long-term exposure to circulating platinum is associated with late effects of treatment in testicular cancer survivorsAnnals of OncologyQ1395.57
89.Mattioli F2016Population pharmacokinetics and probability of target attainment of meropenem in critically ill patientsEuropean Journal of Clinical PharmacologyQ1386.33
90.Zhang J2015Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patientsBritish Journal of Clinical PharmacologyQ1385.43
91.Stockmann C2015Predictive Performance of a Vancomycin Population Pharmacokinetic Model in NeonatesInfectious Diseases and TherapyQ1385.43
92.Andrews LM2018A Population Pharmacokinetic Model to Predict the Individual Starting Dose of Tacrolimus Following Pediatric Renal TransplantationClinical PharmacokineticsQ1379.25
93.Dhawan MS2017Differential toxicity in patients with and without DNA repair mutations: Phase I study of carboplatin and talazoparib in advanced solid tumorsClinical Cancer ResearchQ1377.40
94.Jullien V2017Population pharmacokinetics of micafungin in ICU patients with sepsis and mechanical ventilationJournal of Antimicrobial ChemotherapyQ1377.40
95.Neely M2016Accurately achieving target busulfan exposure in children and adolescents with very limited sampling and the bestdose softwareTherapeutic Drug MonitoringQ2376.17
96.Chiew AL2016Evidence for the changing regimens of acetylcysteineBritish Journal of Clinical PharmacologyQ1376.17
97.Quartino AL2016Population pharmacokinetic and exposure-response analysis for trastuzumab administered using a subcutaneous “manual syringe” injection or intravenously in women with HER2-positive early breast cancerCancer Chemotherapy and PharmacologyQ1376.17
98.Vermeersch S2015Translational pharmacodynamics of calcitonin gene-related peptide monoclonal antibody LY2951742 in a capsaicin-induced dermal blood flow modelJournal of Pharmacology and Experimental TherapeuticsQ1375.29
99.Hoglund RM2015Artemether-lumefantrine co-administration with antiretrovirals: Population pharmacokinetics and dosing implicationsBritish Journal of Clinical PharmacologyQ1375.29
100.Liu XB2018Population pharmacokinetics of voriconazole and CYP2C19 polymorphisms for optimizing dosing regimens in renal transplant recipientsBritish Journal of Clinical PharmacologyQ1367.20
Supplementary Table ST3. Detailed information on the antineoplastic drug class as reported in the top 100 cited articles about PK(/PD) modelling
InformationPercentage of articles
1964-2021 (n= 21)2015-2021 (n = 23)
Population Adult Paediatric Adult and paediatric100% (21) - -91.3% (21) 4.3% (1) 4.3% (1)
Disease Cancer Solid cancer Haematological cancera Combination of solid cancer and haematological cancer Others Rheumatoid Arthritis Neovascular age-related macular degeneration Hematopoietic cell transplantation90.5% (19) 73.7% (14) 15.8% (3) 10.5% (2) 9.5% (2) 50% (1) 50% (1) -87% (20) 80% (16) 15% (3) 5% (1) 13% (3) - - 100% (3)
Drugs Monoclonal antibody Protein kinase inhibitors Plant Alkaloid Antimetabolites Alkylating agents Other antineoplastic agents28.6% (6) 23.8% (5) 19% (4) 4.8% (1) 14.3% (3) 9.5% (2)39.1% (9) 26.1% (6) 4.3% (1) - 13% (3) 17.4% (4)
Supplementary Table ST4. Detailed information on the antibacterial drug class as reported in the top 100 cited articles about PK(/PD) modelling.
InformationPercentage of articles
1964-2021 (n= 12)2015-2021 (n =19)
Populations Adult Paediatric Adult and paediatric100% (12) -68.4% (13) 26.3% (5) 5.3% (1)
Drugs Polymyxins Glycopeptides (Vancomycin, Oritavancin, dalbavancin) Meropenem Fluroquinolones Other antibacterials (Fosfomycin) Other cephalosporins and penems (Ceftolozane/tazobactam) Amoxicillin and beta lactamase inhibitors41.7% (5) 8.3% (1) 25% (3) 25% (3) - - -10.5% (2) 36.8% (7) 21.1% (4) 5.3% (1) 5.3% (1) 15.8% (3) 5.3% (1)
Supplementary Table ST5. Detailed information on the immunosuppressants drug classes as reported in the top 100 cited articles about PK(/PD) modelling
InformationPercentage of articles
1964-2021 (n=9)2015-2021 (n = 17)
Populations Adult Paediatric Adult and paediatric80% (7) - 20% (2)71% (12) 12% (2) 17% (3)
Disease Transplantation Haemopoietic cell transplantation Renal transplant Kidney and heart transplant Inflammatory Bowel Disease Rheumatoid arthritis Mendelian interferonopathies Paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic-uremic syndrome44.4% (4) 25% (1) 50% (2) 25% (1) 44.4% (4) 11.2% (1) - -47% (8) 50% (4) 50% (4) - 23% (4) 18% (3) 6% (1) 6% (1)
Drugs Selective immunosupressants Tumor necrosis factor- alpha inhibitors Calcineurin inhibitors33.3% (3) 44.4% (4) 22.2% (2)52.9% (9) 23.5% (4) 23.5% (4)
Figure 2: Trends in Anatomical Therapeutic Classification (ATC) groups/drug classes in top 100 most cited articles since inception, and in the recent years (2015-2021).: Some studies did not have an ATC number as they are under chemical/plants classification, hence they were not included in the analysis. A total of 93 studies with an ATC number were included in Figure (a), and 95 studies for Figure (b).
Figure 3: Network visualisation map of the co-authorship between countries for the top 100 most cited publications between 1964 and 2021.: Each circle represents a country, and a line connecting the circles indicates countries that appeared as the authors’ countries together in any of the top 100 most cited articles. A larger circle represents a higher number of articles. The link strength attribute indicates the numbers of collaboration between different countries. A higher total link strength indicates a higher collaboration between these countries.
Figure 4: Network visualisation map of the co-authorship between countries for the top 100 most cited publications in the recent years (2015-2021).: Each circle represents a country, and a line connecting the circles indicates countries that appeared as the authors’ countries together in any of the top 100 most cited articles. A larger circle represents a higher number of articles. The link strength attribute indicates the numbers of collaboration between different countries. A higher total link strength indicates a higher collaboration between these countries.
Supplementary Figure: Prisma Flowchart illustrating the Process of Allocation of the 100 Most Cited Articles for the recent years. (2015 -2021).

DISCUSSION

To the best of our knowledge, this is the first study to summarise the top 100 most cited articles in the field of population PK, PD or PKPD modelling using the bibliometric approach. Moreover, we also showed how influential research landscape changed over time in the aforementioned field.

It has been suggested that articles that exceed the threshold of 100 citations can be considered “classic articles”, a sort of “milestones” in the development of a specific area.[22, 23] Since the number of citations for the 100 most cited articles for overall publications exceeds 100 citations, all the articles listed for overall publications can be considered “classic”. Knowledge and understanding of these classic papers can help guide education and provide additional insights into a better understanding of a specific field.[24] This study also found that during the recent years, there has been an increase in the number of publications published in Q1 journals, indicating that over time high impact journals became even more impactful.

This study found that the majority of the impactful articles used population PK modelling to analyse data. This is not surprising as PK data are in many cases easier to collect/measure and evaluate than PD data. Additionally, population PK is an established field with a specific regulatory guidance and many methodological articles on model development and diagnostics.[25, 26] PD results can, however, depend strongly on the disease, and the techniques for their analysis can thus be more difficult to unify. Still, recently, researchers started giving more emphasis to PD, especially to how PK affects PD; which is reflected also in a greater proportion of PKPD studies within the impactful articles. This may also be a consequence of regulatory recommendations, e.g. in 2016, the European Medicines Agency (EMA) published the "Guideline on the use of pharmacokinetics and pharmacodynamics in the development of antibacterial medicinal products[3] that focuses on the use of PKPD analyses to identify potentially efficacious dosing regimens.

Recently, in the top 100 most cited articles, there have been more studies looking at antibacterial and immunosuppressant classes of drugs (Figure 2). In the anti-infectives ATC classification, antimicrobials had the largest increase, possibly another consequence of the aforementioned EMA guidance[3] on the emerging research in this field. The increase was most prominent in special patient populations, where research was/is lacking the most, such as, the critically ill patients,[27, 28] extremely obese patients[29] or neonates.[30–32] In the chemotherapeutic and immunomodulating ATC class, most articles analysed PK(/PD) data of antineoplastic agents, which have remained the most cited over time. This may be due to cancer treatment being a continued important area of interest for the pharmaceutical industry, and one of the fastest growing areas in personalised medicines.[33] Over time, monoclonal antibodies (mAbs) have remained the most researched antineoplastic drugs in the top 100 most cited articles. This is in line with mAbs becoming a significant class of therapeutic drugs available;[34] to date, there are more than 100 mAbs approved by the US Food and Drug Administration.[35]

NONMEM® software was the most widely used software, which remained unchanged over the years. This is expected, given that NONMEM® was the first software package developed by Lewis Sheiner and Stuart Beal to handle complex PK calculations in the nonlinear mixed effect modelling approach.[36, 37] Furthermore, it is widely regarded as the gold standard in population pharmacokinetic-pharmacodynamic modelling.[38] Recently, the percentage of the influential articles that used NONMEM® increased further, despite other emerging software such as Pumas® which is gaining attention and slowly getting recognition.[39, 40]

We also found that recently, there has been an increase in the number of publications involving partnerships between developed and developing countries. One of the potential reasons could be the efforts that were made to promote global collaboration, such as the joint meetings of the Population Approach Group of Australia and New Zealand (PAGANZ, https://www.paganz.org/) with other population approach organizations groups such as the pharmacometrics research group in South Africa in 2002 and the group in Japan in 2006.[41] Moreover, an international collaboration between developed countries and developing countries in scientific research is an effective way to build scientific capacity and share resources.[42] Authors from US-based institutions were found to be most collaborative (Figure 4), probably a consequence of the large number of US-based researchers.

Funding support is an important part of research. Although majority of the 100 most cited articles were funded locally, there was a slight increase of articles that received international funding. This shows that with the availability of international funding support, countries that do not have significant national research budgets could perform highly cited population modelling studies and thus reach beyond national borders.

We also found that there were (mostly the same) top five journals that published 43-44% of all 100 most cited articles (Table 5), showing that if an article is published in one of these journals it likely has a higher probability of becoming an impactful, highly cited article. This may be valuable information for researchers who are newer in this field.

One of the limitations of this work may be the limited search involving only the Scopus database, while other conventional medicine databases, such as Web of Science, and Google Scholar, were not searched. Scopus database was selected as it provides about 20% more coverage than Web of Science, while Google Scholar can deliver results of inconsistent accuracy.[43, 44] Still, there is a possibility that some influential papers might have been overlooked. Additionally, manuscripts that did not report author-provided keywords, which were needed for the current analysis, had to be excluded as these were needed for the bibliometric analysis. Furthermore, as this study only focused on the 100 most cited articles, it should be kept in mind that the results/trends may not be representative of all published articles on population modelling. However, focusing on only these most impactful articles enabled us to confirm that each of the articles were indeed about our topic of interest, and to explore and compare the trends in more detail. One should also note that the citation count does not directly indicate the quality of an article but rather only enables a quantitative evaluation of the scientific impact of an article in a specified research field. Additionally, because citations accumulate over time, papers published earlier understandably have a higher chance of receiving more citations than those published later, making this an important consideration when using the citation count to rank individual papers; we tried to address this by calculating the number of citations per year (since an article has been published) (Supplementary Tables 1 and 2).

We hope that our work will encourage research on topics and/or populations that are currently less represented in such impactful highly cited articles. For example, as the majority of the impactful studies described in the top 100 most cited articles were population PK studies, the field would benefit in focusing (even more) on population PD or PKPD studies, to e.g. increase knowledge of the drug effects and their relationship with the PK too. Although the trends of highly cited papers appear to be slowly improving when involving the paediatric population, there is much room for research and improvement in this special population. It is likely, however, that the current most popular topics in this field will continue to gain attention and influence in the research community in the future.

CONCLUSION

We bibliometrically explored the 100 most cited articles in the population PK, PD or PKPD modelling and the research trends in this field over time. Majority of the studies described in the 100 most cited articles were published by top five journals and were population PK modelling studies looking into immunosuppressant or antibacterial drug data, involving adult population, and using NONMEM® for the analyses. There was a positive shift from studies using PK only models to PKPD models in the recent years. Apart from that no other metric that we looked at changed dramatically in the 100 most cited articles in the recent years, compared to from inception.

Conflict of Interest

The authors declare that there is no conflict of interest.

Author Contributions

NM performed the analysis and wrote the manuscript. HZ designed the research and reviewed the manuscript. EG designed the research, wrote, and reviewed the manuscript.